Product Description
Tuxobertinib (BDTX-189) is an irreversible, orally active, ATP-competitive EGFR/HER2 inhibitor. It is being developed by Black Diamond Therapeutics as a therapy for cancers that are driven by oncogenic allosteric, activating mutations of the EGFR and ErbB2 (HER2).
Mechanisms of Action: EGFR Antagonist,ERBB2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Oncology Solid Tumor Unspecified *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Black Diamond Therapeutics
Company Location: CAMBRIDGE MA 02142
Company CEO: David M. Epstein
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Endometrial Cancer|Biliary Tract Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer|Breast Cancer|Gastrointestinal Cancer|Bladder Cancer|Small Cell Lung Cancer|Cervical Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MasterKey-01 | P2 |
Terminated |
Small Cell Lung Cancer|Breast Cancer|Non-Small-Cell Lung Cancer|Biliary Tract Cancer|Cervical Cancer |
2022-09-02 |
|
| MasterKey-01 | P2 |
Terminated |
Bladder Cancer|Breast Cancer|Gastrointestinal Cancer|Endometrial Cancer|Small Cell Lung Cancer|Biliary Tract Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer |
2022-09-02 |
57% |